ArticleCancer medicine2023
Establishment and validation of systematic prognostic nomograms in patients over 60 years of age with osteosarcoma: A multicenter external verification study.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to develop and validate systematic nomograms to predict cancer specific survival (CSS) and overall survival (OS) in osteosarcoma patients aged over 60 years.
methodsWe used data from the Surveillance, Epidemiology, and End Results (SEER) database and identified 982 patients with osteosarcoma over 60 years of age diagnosed between 2004 and 2015. Overall, 306 patients met the requirements for the training group. Next, we enrolled 56 patients who met the study requirements from multiple medical centers as the external validation group to validate and analyze our model. We collected all available variables and finally selected eight that were statistically associated with CSS and OS through Cox regression analysis. Integrating the identified variables, we constructed 3- and 5-year OS and CSS nomograms, respectively, which were further evaluated by calculating the C-index. A calibration curve was used to evaluate the accuracy of the model. Receiver operating characteristic (ROC) curves measured the predictive capacity of the nomograms. The Kaplan-Meier analysis was used for all patient-based variables to explore the influence of various factors on patient survival. Finally, a decision curve analysis (DCA) curve was used to analyze whether our model would be suitable for application in clinical practice.
resultsCox regression analysis of clinical variables identified age, sex, marital status, tumor grade, tumor laterality, tumor size, M-stage, and surgical treatment as prognostic factors. Nomograms showed good predictive capacity for OS and CSS. We calculated that the C-index of the OS nomogram of the training population was 0.827 (95% CI 0.778-0.876), while that of the CSS nomogram was 0.722 (95% CI 0.665-0.779). The C-index of the OS nomogram evaluated on the external validation population was 0.716 (95% CI 0.575-0.857), while that of the CSS nomogram was 0.642 (95% CI 0.50-0.788). Furthermore, the calibration curve of our prediction models indicated the nomograms could accurately predict patient outcome.
conclusionsThe constructed nomogram is a useful tool for accurately predicting OS and CSS at 3 and 5 years for patients over 60 years of age with osteosarcoma and can assist clinicians in making appropriate decisions in practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.